Interferon beta-1b (Betaseron, BAY86-5046)
DrugIntravenous therapy according to product information
NCT Number: NCT00882453
The purpose of this observational study is to obtain a survey on physical activity in patients who for the first time have experienced symptoms which indicate a high risk for developing multiple sclerosis (MS) and in patients with recently diagnosed MS, and to obtain information on factors potentially influencing the patients' level of activity.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Many Locations, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Intravenous therapy according to product information
Time frame: At baseline and at Month 24
Time frame: At baseline and at Month 24
Time frame: At baseline and at Month 24
Bayer
Industry
Betaferon Treatment and Exercise Data Gathering IN Early MS
Acronym: BEGIN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07118514
Anxiety Disorders, Autoimmune Diseases
Maringá, Paraná, Brazil
View Trial DetailsNCT05826431
Activity, Motor, Autoimmune Diseases
Seattle, Washington, United States
View Trial DetailsNCT06370403
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Kaunas, Lithuania
View Trial DetailsNCT03967106
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Sheffield, South Yorkshire, United Kingdom
View Trial Details